Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with decompensated cirrhosis: Table 12
  • There are now several regimens with DAAs that are recommended
    • Choice of regimen depends on genotype, treatment experience, and ribavirin eligibility

Action required